Every non-small cell lung cancer patient has a right to their comprehensive biomarker testing results.

Patients with a non-small cell lung cancer (NSCLC) diagnosis should discuss comprehensive biomarker testing with their healthcare team.

**Comprehensive biomarker testing** can identify specific genetic “drivers” (called biomarkers) that cause cancer to grow and spread in different ways. Comprehensive biomarker testing tests for all biomarkers that are recommended for your type and stage of NSCLC, based on the most current clinical guidelines. Use the information included below to help inform your next conversation with your healthcare team about biomarker testing at any decision point before new treatment, including upon diagnosis, recurrence, or progression.

As a lung cancer patient, you have the right to...

- **Receive optimal care and engage in shared decision making** with your healthcare team when discussing your personalized treatment plan.
- **Know if your healthcare team already has completed comprehensive biomarker testing** on your lung cancer, and if so, what the results of your test show.
- **Access and understand your biomarker test results**, which has critical information about whether you may respond to targeted therapy, chemotherapy, or immunotherapy, or be eligible for a clinical trial.
- **Understand the cost of comprehensive biomarker testing** and whether it will be covered by private insurance, Medicare, or a Medicaid plan.
- **Seek a second opinion** about your treatment options based on your biomarker test results.
- **Request a print or electronic copy of your comprehensive biomarker testing report** for your medical records, which can be helpful for seeking a second opinion.

Know your biomarkers. Know your options.

To learn more about biomarkers and to read stories by lung cancer patients and survivors who have experienced comprehensive biomarker testing, visit LUNGevity.org/NoOneMissed.